score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4828	116.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61L (Missense)	1	SARC_MUTECT2	TCGA-DX-AB2E-01A-11D-A38Z-09	TCGA-DX-AB2E-10A-01D-A38Z-09
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.9762	42.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	SARC_MUTECT2	TCGA-IW-A3M5-01A-22D-A21Q-09	TCGA-IW-A3M5-10A-01D-A21Q-09
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546K	0.3396	53.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546K (Missense)	1	SARC_MUTECT2	TCGA-DX-A8BX-01A-11D-A37C-09	TCGA-DX-A8BX-10A-01D-A37F-09
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.1818	44.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	SARC_MUTECT2	TCGA-UE-A6QT-01A-12D-A32I-09	TCGA-UE-A6QT-10B-01D-A32I-09
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.K700E	0.4242	33.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K700E (Missense)		SARC_MUTECT2	TCGA-DX-AB2J-01A-11D-A387-09	TCGA-DX-AB2J-10A-01D-A38A-09
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P341L	0.1369	168.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P341L (Missense)	1	SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P741L	0.4667	75.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P741L (Missense)	1	SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.E227K	0.2162	74.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.E227K (Missense)		SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.R804Q	0.6071	56.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.R804Q (Missense)		SARC_MUTECT2	TCGA-DX-A3UD-01A-11D-A307-09	TCGA-DX-A3UD-10A-01D-A307-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.C906R	0.175	40.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.C906R (Missense)		SARC_MUTECT2	TCGA-QQ-A8VH-01A-11D-A37C-09	TCGA-QQ-A8VH-10A-01D-A37F-09
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.M448R	0.2245	49.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.M448R (Missense)	0	SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13C	0.1316	38.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13C (Missense)	1	SARC_MUTECT2	TCGA-DX-A3LU-01A-11D-A21Q-09	TCGA-DX-A3LU-10A-01D-A21Q-09
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61H	0.6182	55.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61H (Missense)	1	SARC_MUTECT2	TCGA-IW-A3M5-01A-22D-A21Q-09	TCGA-IW-A3M5-10A-01D-A21Q-09
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.S1403Afs*3	0.2	60.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.S1403Afs*3 (Frameshift)		SARC_MUTECT2	TCGA-DX-A6B7-01A-11D-A307-09	TCGA-DX-A6B7-10A-01D-A307-09
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.G894S	0.0909	33.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.G894S (Missense)		SARC_MUTECT2	TCGA-DX-A8BH-01A-11D-A37C-09	TCGA-DX-A8BH-11A-43D-A37F-09
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R886Q	0.3922	51.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R886Q (Missense)		SARC_MUTECT2	TCGA-DX-A3U7-01A-11D-A29N-09	TCGA-DX-A3U7-10A-01D-A29N-09
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.K347Rfs*16	0.4493	69.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.K347Rfs*16 (Frameshift)		SARC_MUTECT2	TCGA-MO-A47P-01A-11D-A24N-09	TCGA-MO-A47P-10A-01D-A24N-09
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.S271Rfs*66	0.4302	86.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.S271Rfs*66 (Frameshift)		SARC_MUTECT2	TCGA-KD-A5QT-01A-11D-A27P-09	TCGA-KD-A5QT-10A-01D-A27P-09
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.T271N	0.4898	49.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.T271N (Missense)		SARC_MUTECT2	TCGA-3B-A9HR-01A-11D-A387-09	TCGA-3B-A9HR-10A-01D-A38A-09
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.I279Yfs*4	0.2086	163.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I279Yfs*4 (Frameshift)		SARC_MUTECT2	TCGA-3B-A9HT-01A-11D-A38Z-09	TCGA-3B-A9HT-10A-01D-A38Z-09
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.A551*	0.5455	22.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.A551* (Frameshift)		SARC_MUTECT2	TCGA-QC-AA9N-01A-11D-A38Z-09	TCGA-QC-AA9N-10A-01D-A38Z-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.Y336Ffs*5	0.8846	26.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y336Ffs*5 (Frameshift)	1	SARC_MUTECT2	TCGA-WK-A8XS-01A-11D-A37C-09	TCGA-WK-A8XS-10E-01D-A37F-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.P30Qfs*24	0.8182	22.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P30Qfs*24 (Frameshift)	1	SARC_MUTECT2	TCGA-WK-A8XY-01A-11D-A37C-09	TCGA-WK-A8XY-10A-01D-A37F-09
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E570D	0.4844	64.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E570D (Missense)		SARC_MUTECT2	TCGA-IS-A3K7-01A-11D-A21Q-09	TCGA-IS-A3K7-10A-01D-A21Q-09
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R852Q	0.425	40.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R852Q (Missense)	1	SARC_MUTECT2	TCGA-MO-A47R-01A-11D-A24N-09	TCGA-MO-A47R-10A-01D-A24N-09
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N345K	0.4054	37.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N345K (Missense)	1	SARC_MUTECT2	TCGA-X6-A7WB-01A-11D-A351-09	TCGA-X6-A7WB-10A-01D-A351-09
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.K886E	0.1696	112.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.K886E (Missense)	1	SARC_MUTECT2	TCGA-HB-A2OT-01A-11D-A21Q-09	TCGA-HB-A2OT-10A-01D-A21Q-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.G887W	0.6957	23.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.G887W (Missense)		SARC_MUTECT2	TCGA-DX-A3UA-01A-12D-A307-09	TCGA-DX-A3UA-10A-01D-A307-09
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.L283F	0.0476	84.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.L283F (Missense)		SARC_MUTECT2	TCGA-DX-A6BA-01A-11D-A307-09	TCGA-DX-A6BA-10A-01D-A307-09
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V378I	0.3333	42.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V378I (Missense)	0	SARC_MUTECT2	TCGA-DX-A3UA-01A-12D-A307-09	TCGA-DX-A3UA-10A-01D-A307-09
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.Q700K	0.0811	74.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.Q700K (Missense)	0	SARC_MUTECT2	TCGA-X6-A7WA-01A-12D-A351-09	TCGA-X6-A7WA-10A-01D-A351-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.I396L	0.12	25.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.I396L (Missense)	1	SARC_MUTECT2	TCGA-MO-A47P-01A-11D-A24N-09	TCGA-MO-A47P-10A-01D-A24N-09
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.T696I	0.2727	33.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.T696I (Missense)	0	SARC_MUTECT2	TCGA-WK-A8XX-01A-11D-A37C-09	TCGA-WK-A8XX-10A-01D-A37F-09
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R403C	0.3514	37.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R403C (Missense)	0	SARC_MUTECT2	TCGA-3B-A9I1-01A-11D-A38Z-09	TCGA-3B-A9I1-10A-01D-A38Z-09
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.T440I	0.2833	60.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.T440I (Missense)	0	SARC_MUTECT2	TCGA-DX-A2IZ-01A-11D-A21Q-09	TCGA-DX-A2IZ-10A-01D-A21Q-09
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.I299F	0.1154	52.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.I299F (Missense)	0	SARC_MUTECT2	TCGA-DX-A6YQ-01A-12D-A33E-09	TCGA-DX-A6YQ-10A-01D-A33H-09
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.D454G	0.2209	86.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.D454G (Missense)	0	SARC_MUTECT2	TCGA-DX-AB32-01A-11D-A417-09	TCGA-DX-AB32-10A-01D-A41A-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.7973	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S1589L	0.7917	96.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S1589L (Missense)	1	SARC_MUTECT2	TCGA-LI-A9QH-01A-11D-A37C-09	TCGA-LI-A9QH-10A-01D-A37F-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2416P	0.575	40.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2416P (Missense)	1	SARC_MUTECT2	TCGA-IW-A3M6-01A-11D-A21Q-09	TCGA-IW-A3M6-10A-01D-A21Q-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L400I	0.2857	91.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L400I (Missense)	1	SARC_MUTECT2	TCGA-MJ-A68J-01A-11D-A307-09	TCGA-MJ-A68J-10A-01D-A307-09
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.D459V	0.1667	30.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.D459V (Missense)	0	SARC_MUTECT2	TCGA-DX-A8BP-01A-11D-A37C-09	TCGA-DX-A8BP-10A-01D-A37F-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S1403I	0.1935	62.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S1403I (Missense)	1	SARC_MUTECT2	TCGA-DX-A6B7-01A-11D-A307-09	TCGA-DX-A6B7-10A-01D-A307-09
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.T323S	0.3509	57.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.T323S (Missense)		SARC_MUTECT2	TCGA-X6-A8C5-01A-11D-A36J-09	TCGA-X6-A8C5-10A-01D-A36M-09
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.I556V	0.2308	26.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.I556V (Missense)		SARC_MUTECT2	TCGA-QQ-A5VA-01A-12D-A32I-09	TCGA-QQ-A5VA-11A-11D-A32I-09
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.S650L	0.2857	70.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.S650L (Missense)		SARC_MUTECT2	TCGA-3B-A9HI-01A-11D-A387-09	TCGA-3B-A9HI-10A-01D-A38A-09
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.A930T	0.1026	39.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.A930T (Missense)		SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1471C	0.4237	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1471C (Missense)		SARC_MUTECT2	TCGA-X6-A7WD-01A-21D-A351-09	TCGA-X6-A7WD-10A-01D-A351-09
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.S964F	0.3333	24.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.S964F (Missense)		SARC_MUTECT2	TCGA-DX-A8BP-01A-11D-A37C-09	TCGA-DX-A8BP-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158H	0.7955	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158H (Missense)		SARC_MUTECT2	TCGA-DX-A48O-01A-11D-A307-09	TCGA-DX-A48O-10A-01D-A307-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	1.0	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		SARC_MUTECT2	TCGA-WP-A9GB-01A-11D-A37C-09	TCGA-WP-A9GB-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E298*	0.7083	72.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E298* (Nonsense)		SARC_MUTECT2	TCGA-QQ-A5V9-01A-11D-A32I-09	TCGA-QQ-A5V9-11A-31D-A32I-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.N268Kfs*77	0.9	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N268Kfs*77 (Frameshift)		SARC_MUTECT2	TCGA-X6-A8C2-01A-11D-A36J-09	TCGA-X6-A8C2-10A-01D-A36M-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.N268Y	0.9048	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N268Y (Missense)		SARC_MUTECT2	TCGA-X6-A8C2-01A-11D-A36J-09	TCGA-X6-A8C2-10A-01D-A36M-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.9412	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		SARC_MUTECT2	TCGA-JV-A5VF-01A-11D-A29N-09	TCGA-JV-A5VF-10A-01D-A29N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H214R	0.8444	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H214R (Missense)		SARC_MUTECT2	TCGA-FX-A3TO-01A-11D-A228-09	TCGA-FX-A3TO-10A-01D-A22A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.7846	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-A6BA-01A-11D-A307-09	TCGA-DX-A6BA-10A-01D-A307-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.4667	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317* (Nonsense)		SARC_MUTECT2	TCGA-IS-A3K7-01A-11D-A21Q-09	TCGA-IS-A3K7-10A-01D-A21Q-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M237I	0.8	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237I (Missense)		SARC_MUTECT2	TCGA-DX-A7EU-01A-22D-A36J-09	TCGA-DX-A7EU-10A-01D-A36M-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.6912	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SARC_MUTECT2	TCGA-DX-A8BV-01A-11D-A37C-09	TCGA-DX-A8BV-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.3929	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-A8BH-01A-11D-A37C-09	TCGA-DX-A8BH-11A-43D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278H	0.975	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278H (Missense)		SARC_MUTECT2	TCGA-DX-AB30-01A-11D-A38Z-09	TCGA-DX-AB30-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275Y	0.4545	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275Y (Missense)		SARC_MUTECT2	TCGA-3B-A9HZ-01A-11D-A38Z-09	TCGA-3B-A9HZ-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.A189Pfs*58	0.84	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A189Pfs*58 (Frameshift)		SARC_MUTECT2	TCGA-N1-A6IA-01A-12D-A32I-09	TCGA-N1-A6IA-11A-11D-A32I-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C238Y	0.4348	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238Y (Missense)		SARC_MUTECT2	TCGA-X6-A8C5-01A-11D-A36J-09	TCGA-X6-A8C5-10A-01D-A36M-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.2917	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		SARC_MUTECT2	TCGA-3B-A9I3-01A-11D-A38Z-09	TCGA-3B-A9I3-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S215R	0.75	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S215R (Missense)		SARC_MUTECT2	TCGA-K1-A6RV-01A-11D-A32I-09	TCGA-K1-A6RV-10A-01D-A32I-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151S	0.9375	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151S (Missense)		SARC_MUTECT2	TCGA-X6-A7WA-01A-12D-A351-09	TCGA-X6-A7WA-10A-01D-A351-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.G262Vfs*83	1.0	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G262Vfs*83 (Frameshift)		SARC_MUTECT2	TCGA-HB-A43Z-01A-11D-A24N-09	TCGA-HB-A43Z-10A-01D-A24N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X332_splice	0.8378	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X332_splice (Splice Site)		SARC_MUTECT2	TCGA-SG-A6Z4-01A-22D-A33E-09	TCGA-SG-A6Z4-10A-01D-A33H-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220H	0.3462	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220H (Missense)		SARC_MUTECT2	TCGA-QQ-A5VA-01A-12D-A32I-09	TCGA-QQ-A5VA-11A-11D-A32I-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C238Y	0.8293	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238Y (Missense)		SARC_MUTECT2	TCGA-K1-A3PN-01A-11D-A228-09	TCGA-K1-A3PN-10A-01D-A22A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175L	0.8958	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175L (Missense)		SARC_MUTECT2	TCGA-DX-A48U-01A-11D-A307-09	TCGA-DX-A48U-10A-01D-A307-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R213Dfs*34	0.8083	120.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213Dfs*34 (Frameshift)		SARC_MUTECT2	TCGA-LI-A67I-01A-31D-A307-09	TCGA-LI-A67I-10A-01D-A307-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y205C	0.7647	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205C (Missense)		SARC_MUTECT2	TCGA-IW-A3M5-01A-22D-A21Q-09	TCGA-IW-A3M5-10A-01D-A21Q-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y126C	0.5	8.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y126C (Missense)		SARC_MUTECT2	TCGA-DX-A6YU-01A-12D-A33E-09	TCGA-DX-A6YU-10A-01D-A33H-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.6452	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		SARC_MUTECT2	TCGA-PC-A5DK-01A-11D-A27P-09	TCGA-PC-A5DK-10A-01D-A27P-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.85	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		SARC_MUTECT2	TCGA-DX-AB2X-01A-11D-A387-09	TCGA-DX-AB2X-10A-01D-A38A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.65	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		SARC_MUTECT2	TCGA-3B-A9HP-01A-11D-A387-09	TCGA-3B-A9HP-10A-01D-A38A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M237I	0.4661	118.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237I (Missense)		SARC_MUTECT2	TCGA-DX-A3M2-01A-21D-A228-09	TCGA-DX-A3M2-10A-01D-A22A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.4474	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		SARC_MUTECT2	TCGA-DX-A7EN-01A-11D-A38Z-09	TCGA-DX-A7EN-11A-11D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V203L	0.4865	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V203L (Missense)		SARC_MUTECT2	TCGA-DX-A7EN-01A-11D-A38Z-09	TCGA-DX-A7EN-11A-11D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179N	0.8571	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179N (Missense)		SARC_MUTECT2	TCGA-KD-A5QT-01A-11D-A27P-09	TCGA-KD-A5QT-10A-01D-A27P-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D259V	0.6897	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D259V (Missense)		SARC_MUTECT2	TCGA-WK-A8XX-01A-11D-A37C-09	TCGA-WK-A8XX-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.8621	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		SARC_MUTECT2	TCGA-DX-A6BB-01A-12D-A32I-09	TCGA-DX-A6BB-10A-01D-A32I-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.6765	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-A8BK-01A-11D-A37C-09	TCGA-DX-A8BK-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G266R	0.1698	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G266R (Missense)		SARC_MUTECT2	TCGA-K1-A6RT-01A-32D-A33E-09	TCGA-K1-A6RT-10A-01D-A33H-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G244S	0.8889	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G244S (Missense)		SARC_MUTECT2	TCGA-3B-A9I1-01A-11D-A38Z-09	TCGA-3B-A9I1-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R213P	0.5893	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213P (Missense)		SARC_MUTECT2	TCGA-IE-A4EJ-01A-11D-A24N-09	TCGA-IE-A4EJ-10A-01D-A24N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R156G	0.4737	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R156G (Missense)		SARC_MUTECT2	TCGA-3B-A9HX-01A-11D-A38Z-09	TCGA-3B-A9HX-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L130Hfs*16	0.6111	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L130Hfs*16 (Frameshift)		SARC_MUTECT2	TCGA-DX-A1KX-01A-22D-A24N-09	TCGA-DX-A1KX-10A-01D-A24N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y234C	0.9455	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y234C (Missense)		SARC_MUTECT2	TCGA-IE-A4EH-01A-11D-A24N-09	TCGA-IE-A4EH-10A-01D-A24N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R335Vfs*10	0.6471	17.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R335Vfs*10 (Frameshift)		SARC_MUTECT2	TCGA-WK-A8Y0-01A-11D-A417-09	TCGA-WK-A8Y0-10D-01D-A41A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.8889	18.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		SARC_MUTECT2	TCGA-DX-A48J-01A-21D-A307-09	TCGA-DX-A48J-10A-01D-A307-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q167*	0.9	10.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q167* (Nonsense)		SARC_MUTECT2	TCGA-DX-AATS-01A-12D-A417-09	TCGA-DX-AATS-10A-01D-A41A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.N288Kfs*59	0.6986	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N288Kfs*59 (Frameshift)		SARC_MUTECT2	TCGA-DX-A6Z0-01A-13D-A36J-09	TCGA-DX-A6Z0-10B-01D-A36M-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.T256Ifs*90	0.84	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T256Ifs*90 (Frameshift)		SARC_MUTECT2	TCGA-DX-A8BU-01A-11D-A37C-09	TCGA-DX-A8BU-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C242S	0.881	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242S (Missense)		SARC_MUTECT2	TCGA-QC-A6FX-01A-11D-A32I-09	TCGA-QC-A6FX-10B-01D-A32I-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.7083	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		SARC_MUTECT2	TCGA-3B-A9HQ-01A-11D-A387-09	TCGA-3B-A9HQ-10A-01D-A38A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.C275Lfs*70	0.4	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275Lfs*70 (Frameshift)		SARC_MUTECT2	TCGA-QQ-A5VB-01A-11D-A36J-09	TCGA-QQ-A5VB-11B-11D-A36M-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286K	0.5	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286K (Missense)		SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.2222	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		SARC_MUTECT2	TCGA-DX-A2J1-01A-11D-A21Q-09	TCGA-DX-A2J1-10A-01D-A21Q-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.2593	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		SARC_MUTECT2	TCGA-QQ-A5VD-01A-21D-A32I-09	TCGA-QQ-A5VD-10A-01D-A32I-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R209Kfs*6	0.7419	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R209Kfs*6 (Frameshift)		SARC_MUTECT2	TCGA-MB-A5YA-01A-11D-A29N-09	TCGA-MB-A5YA-10A-01D-A29N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337L	0.8333	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337L (Missense)		SARC_MUTECT2	TCGA-IS-A3KA-01A-11D-A21Q-09	TCGA-IS-A3KA-10A-01D-A21Q-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K132R	0.5385	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K132R (Missense)		SARC_MUTECT2	TCGA-DX-AB2W-01A-11D-A38Z-09	TCGA-DX-AB2W-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G244S	0.7831	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G244S (Missense)		SARC_MUTECT2	TCGA-X6-A7WC-01A-12D-A351-09	TCGA-X6-A7WC-10A-01D-A351-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.W91*	0.7619	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W91* (Nonsense)		SARC_MUTECT2	TCGA-HB-A5W3-01A-11D-A29N-09	TCGA-HB-A5W3-10A-01D-A29N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220D	0.8036	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220D (Missense)		SARC_MUTECT2	TCGA-DX-A3UF-01A-11D-A307-09	TCGA-DX-A3UF-10A-01D-A307-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.6774	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		SARC_MUTECT2	TCGA-3B-A9HU-01A-11D-A38Z-09	TCGA-3B-A9HU-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K132R	0.5526	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K132R (Missense)		SARC_MUTECT2	TCGA-IF-A4AJ-01A-11D-A24N-09	TCGA-IF-A4AJ-11A-12D-A24N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K351E	0.6296	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K351E (Missense)		SARC_MUTECT2	TCGA-DX-A6Z2-01A-12D-A36J-09	TCGA-DX-A6Z2-11A-11D-A36M-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q136*	0.875	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q136* (Nonsense)		SARC_MUTECT2	TCGA-X6-A7WB-01A-11D-A351-09	TCGA-X6-A7WB-10A-01D-A351-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.E336Afs*10	0.7692	13.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E336Afs*10 (Frameshift)		SARC_MUTECT2	TCGA-IE-A4EI-01A-11D-A24N-09	TCGA-IE-A4EI-10A-01D-A24N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179Q	0.0909	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179Q (Missense)		SARC_MUTECT2	TCGA-VT-A80J-01A-11D-A36J-09	TCGA-VT-A80J-11A-22D-A36M-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.9892	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		SARC_MUTECT2	TCGA-LI-A9QH-01A-11D-A37C-09	TCGA-LI-A9QH-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.25	96.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		SARC_MUTECT2	TCGA-MB-A5Y9-01A-11D-A29N-09	TCGA-MB-A5Y9-10A-01D-A29N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K132E	0.8462	13.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K132E (Missense)		SARC_MUTECT2	TCGA-WK-A8XZ-01A-11D-A37C-09	TCGA-WK-A8XZ-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.9444	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		SARC_MUTECT2	TCGA-WK-A8XY-01A-11D-A37C-09	TCGA-WK-A8XY-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F270V	0.65	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F270V (Missense)		SARC_MUTECT2	TCGA-IS-A3K6-01A-11D-A21Q-09	TCGA-IS-A3K6-10A-01D-A21Q-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.8667	15.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		SARC_MUTECT2	TCGA-DX-AB2E-01A-11D-A38Z-09	TCGA-DX-AB2E-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X119_splice	0.6364	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X119_splice (Splice Site)		SARC_MUTECT2	TCGA-Z4-AAPG-01A-11D-A38Z-09	TCGA-Z4-AAPG-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.W91*	0.2407	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W91* (Nonsense)		SARC_MUTECT2	TCGA-3B-A9HT-01A-11D-A38Z-09	TCGA-3B-A9HT-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C135R	0.5556	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C135R (Missense)		SARC_MUTECT2	TCGA-DX-A8BP-01A-11D-A37C-09	TCGA-DX-A8BP-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.1707	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		SARC_MUTECT2	TCGA-UE-A6QT-01A-12D-A32I-09	TCGA-UE-A6QT-10B-01D-A32I-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V73Rfs*76	0.8462	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V73Rfs*76 (Frameshift)		SARC_MUTECT2	TCGA-DX-A6B8-01A-11D-A307-09	TCGA-DX-A6B8-10A-01D-A307-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.7619	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		SARC_MUTECT2	TCGA-3B-A9HY-01A-11D-A38Z-09	TCGA-3B-A9HY-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y163N	0.8148	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y163N (Missense)		SARC_MUTECT2	TCGA-QQ-A8VH-01A-11D-A37C-09	TCGA-QQ-A8VH-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E224D	0.4062	96.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E224D (Missense)		SARC_MUTECT2	TCGA-3B-A9HV-01A-11D-A38Z-09	TCGA-3B-A9HV-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L194R	0.4557	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L194R (Missense)		SARC_MUTECT2	TCGA-3B-A9HV-01A-11D-A38Z-09	TCGA-3B-A9HV-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I195F	0.4182	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195F (Missense)		SARC_MUTECT2	TCGA-KF-A41W-01A-11D-A24N-09	TCGA-KF-A41W-10A-01D-A24N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.K120Tfs*2	0.4765	149.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K120Tfs*2 (Nonsense)		SARC_MUTECT2	TCGA-DX-A7ET-01A-11D-A36J-09	TCGA-DX-A7ET-10A-01D-A36M-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275Y	0.8636	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275Y (Missense)		SARC_MUTECT2	TCGA-DX-A6B7-01A-11D-A307-09	TCGA-DX-A6B7-10A-01D-A307-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.8218	202.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-AB2V-01A-11D-A417-09	TCGA-DX-AB2V-10A-01D-A41A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X331_splice	0.9362	94.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X331_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-A48V-01A-11D-A307-09	TCGA-DX-A48V-10A-01D-A307-09
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.E409K	0.1803	61.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.E409K (Missense)		SARC_MUTECT2	TCGA-QQ-A5VD-01A-21D-A32I-09	TCGA-QQ-A5VD-10A-01D-A32I-09
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.A272T	0.3733	75.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.A272T (Missense)		SARC_MUTECT2	TCGA-WK-A8XS-01A-11D-A37C-09	TCGA-WK-A8XS-10E-01D-A37F-09
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.F746V	0.0909	44.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.F746V (Missense)		SARC_MUTECT2	TCGA-DX-A3LU-01A-11D-A21Q-09	TCGA-DX-A3LU-10A-01D-A21Q-09
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.T12Hfs*53	0.2308	78.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.T12Hfs*53 (Frameshift)		SARC_MUTECT2	TCGA-3B-A9HX-01A-11D-A38Z-09	TCGA-3B-A9HX-10A-01D-A38Z-09
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.D11Hfs*53	0.2375	80.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.D11Hfs*53 (Frameshift)		SARC_MUTECT2	TCGA-3B-A9HX-01A-11D-A38Z-09	TCGA-3B-A9HX-10A-01D-A38Z-09
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G653V	0.2	15.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G653V (Missense)		SARC_MUTECT2	TCGA-DX-A8BT-01A-11D-A37C-09	TCGA-DX-A8BT-10A-01D-A37F-09
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.T195M	0.0968	31.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.T195M (Missense)		SARC_MUTECT2	TCGA-DX-AB32-01A-11D-A417-09	TCGA-DX-AB32-10A-01D-A41A-09
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.T508A	0.2941	34.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.T508A (Missense)		SARC_MUTECT2	TCGA-IF-A4AJ-01A-11D-A24N-09	TCGA-IF-A4AJ-11A-12D-A24N-09
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.R110*	0.9032	31.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R110* (Nonsense)		SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R676W	0.4	25.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R676W (Missense)		SARC_MUTECT2	TCGA-3B-A9HT-01A-11D-A38Z-09	TCGA-3B-A9HT-10A-01D-A38Z-09
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.S336Rfs*42	0.2222	36.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.S336Rfs*42 (Frameshift)		SARC_MUTECT2	TCGA-3B-A9HT-01A-11D-A38Z-09	TCGA-3B-A9HT-10A-01D-A38Z-09
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.Q356Vfs*34	0.5909	22.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.Q356Vfs*34 (Frameshift)		SARC_MUTECT2	TCGA-DX-AB2O-01A-12D-A38Z-09	TCGA-DX-AB2O-10A-01D-A38Z-09
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P326T	0.0746	67.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P326T (Missense)		SARC_MUTECT2	TCGA-DX-A48L-01A-11D-A307-09	TCGA-DX-A48L-10A-01D-A307-09
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.R566H	0.25	16.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.R566H (Missense)		SARC_MUTECT2	TCGA-3B-A9HT-01A-11D-A38Z-09	TCGA-3B-A9HT-10A-01D-A38Z-09
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Splice Site	p.X30_splice	0.1905	21.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.X30_splice (Splice Site)	1	SARC_MUTECT2	TCGA-DX-AB32-01A-11D-A417-09	TCGA-DX-AB32-10A-01D-A41A-09
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Splice Site	p.X984_splice	0.4634	82.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.X984_splice (Splice Site)	1	SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.N633K	0.1034	29.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.N633K (Missense)	0	SARC_MUTECT2	TCGA-DX-A3LU-01A-11D-A21Q-09	TCGA-DX-A3LU-10A-01D-A21Q-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.T219Lfs*11	0.3704	27.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.T219Lfs*11 (Frameshift)	0	SARC_MUTECT2	TCGA-MO-A47R-01A-11D-A24N-09	TCGA-MO-A47R-10A-01D-A24N-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.V1804I	0.5294	17.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.V1804I (Missense)	0	SARC_MUTECT2	TCGA-IS-A3K7-01A-11D-A21Q-09	TCGA-IS-A3K7-10A-01D-A21Q-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	RET	Nonsense	p.S859*	0.4074	27.0	0.0	0.0		Investigate Actionability	Selpercatinib	RET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.	Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.S859* (Nonsense)		SARC_MUTECT2	TCGA-DX-AB2X-01A-11D-A387-09	TCGA-DX-AB2X-10A-01D-A38A-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.I605Yfs*9	0.3478	46.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.I605Yfs*9 (Frameshift)	0	SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Frameshift	p.Q556Rfs*8	0.6429	56.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 	Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.Q556Rfs*8 (Frameshift)	0	SARC_MUTECT2	TCGA-MO-A47R-01A-11D-A24N-09	TCGA-MO-A47R-10A-01D-A24N-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Frameshift	p.W557Gfs*18	0.6316	57.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 	Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.W557Gfs*18 (Frameshift)	0	SARC_MUTECT2	TCGA-MO-A47R-01A-11D-A24N-09	TCGA-MO-A47R-10A-01D-A24N-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.T155S	0.46	50.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.T155S (Missense)		SARC_MUTECT2	TCGA-DX-A8BV-01A-11D-A37C-09	TCGA-DX-A8BV-10A-01D-A37F-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.5714	56.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		SARC_MUTECT2	TCGA-DX-AB2E-01A-11D-A38Z-09	TCGA-DX-AB2E-10A-01D-A38Z-09
Investigate Actionability	FDA-Approved		Clinical trial	Somatic Variant	PIK3CA	Frameshift	p.N1068Kfs*5	0.4286	21.0	0.0	0.0		Investigate Actionability	Alpelisib	PI3K/AKT/mTOR inhibition	Targeted therapy	Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. 	Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N1068Kfs*5 (Frameshift)	1	SARC_MUTECT2	TCGA-Z4-A9VC-01A-11D-A37C-09	TCGA-Z4-A9VC-10A-01D-A37F-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.K1078E	0.2549	51.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.K1078E (Missense)	1	SARC_MUTECT2	TCGA-WP-A9GB-01A-11D-A37C-09	TCGA-WP-A9GB-10A-01D-A37F-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.A755D	0.0667	105.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.A755D (Missense)	1	SARC_MUTECT2	TCGA-DX-A6YV-01A-12D-A351-09	TCGA-DX-A6YV-10B-01D-A351-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.G324C	0.4138	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.G324C (Missense)	1	SARC_MUTECT2	TCGA-DX-A8BJ-01A-11D-A417-09	TCGA-DX-A8BJ-10B-01D-A41A-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.A407T	0.3919	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.A407T (Missense)	0	SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.L226F	0.4471	85.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.L226F (Missense)	0	SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.E180K	0.1667	24.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E180K (Missense)	0	SARC_MUTECT2	TCGA-QQ-A5VD-01A-21D-A32I-09	TCGA-QQ-A5VD-10A-01D-A32I-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.K503T	0.4483	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.K503T (Missense)	0	SARC_MUTECT2	TCGA-WK-A8XT-01A-11D-A37C-09	TCGA-WK-A8XT-10A-01D-A37F-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.H593Y	0.2545	55.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.H593Y (Missense)	0	SARC_MUTECT2	TCGA-DX-AB2E-01A-11D-A38Z-09	TCGA-DX-AB2E-10A-01D-A38Z-09
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Splice Site	p.X91_splice	0.0652	46.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.X91_splice (Splice Site)	0	SARC_MUTECT2	TCGA-DX-AB30-01A-11D-A38Z-09	TCGA-DX-AB30-10A-01D-A38Z-09
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.A817D	0.125	48.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.A817D (Missense)		SARC_MUTECT2	TCGA-DX-A6YV-01A-12D-A351-09	TCGA-DX-A6YV-10B-01D-A351-09
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.V892I	0.2338	77.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.V892I (Missense)		SARC_MUTECT2	TCGA-DX-AB32-01A-11D-A417-09	TCGA-DX-AB32-10A-01D-A41A-09
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.S403F	0.6628	86.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.S403F (Missense)	0	SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P515L	0.3704	81.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P515L (Missense)	0	SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.D639V	0.186	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.D639V (Missense)	0	SARC_MUTECT2	TCGA-K1-A6RU-01A-11D-A32I-09	TCGA-K1-A6RU-10A-01D-A32I-09
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.A246S	0.1176	51.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.A246S (Missense)	0	SARC_MUTECT2	TCGA-DX-A6YT-01A-21D-A351-09	TCGA-DX-A6YT-10B-01D-A351-09
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Splice Site	p.X106_splice	0.0833	72.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.X106_splice (Splice Site)	0	SARC_MUTECT2	TCGA-3B-A9HU-01A-11D-A38Z-09	TCGA-3B-A9HU-10A-01D-A38Z-09
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.Y948C	0.6809	47.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.Y948C (Missense)		SARC_MUTECT2	TCGA-DX-A7EF-01A-11D-A33E-09	TCGA-DX-A7EF-10A-01D-A33H-09
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.C1709Y	0.4186	43.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.C1709Y (Missense)		SARC_MUTECT2	TCGA-DX-A3UA-01A-12D-A307-09	TCGA-DX-A3UA-10A-01D-A307-09
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.R1712K	0.4	40.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.R1712K (Missense)		SARC_MUTECT2	TCGA-DX-A3UA-01A-12D-A307-09	TCGA-DX-A3UA-10A-01D-A307-09
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S1820T	0.375	24.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S1820T (Missense)		SARC_MUTECT2	TCGA-DX-A3UA-01A-12D-A307-09	TCGA-DX-A3UA-10A-01D-A307-09
Investigate Actionability	Guideline			Somatic Variant	TET2	Deletion	p.S1760del	0.2308	13.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S1760del (Deletion)		SARC_MUTECT2	TCGA-QC-A6FX-01A-11D-A32I-09	TCGA-QC-A6FX-10B-01D-A32I-09
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.I1871V	0.5	14.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.I1871V (Missense)		SARC_MUTECT2	TCGA-QQ-A8VB-01A-11D-A37C-09	TCGA-QQ-A8VB-10A-01D-A37F-09
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L1065F	0.4118	17.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L1065F (Missense)		SARC_MUTECT2	TCGA-DX-A3LY-01B-11D-A27P-09	TCGA-DX-A3LY-10B-01D-A27P-09
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.S743T	0.4381	105.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S743T (Missense)		SARC_MUTECT2	TCGA-DX-A6BF-01A-11D-A307-09	TCGA-DX-A6BF-10A-01D-A307-09
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.A290D	0.0519	135.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.A290D (Missense)		SARC_MUTECT2	TCGA-X6-A7WA-01A-12D-A351-09	TCGA-X6-A7WA-10A-01D-A351-09
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Frameshift	p.F1088Lfs*5	0.2955	88.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.F1088Lfs*5 (Frameshift)		SARC_MUTECT2	TCGA-DX-AB32-01A-11D-A417-09	TCGA-DX-AB32-10A-01D-A41A-09
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R982K	0.3022	139.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R982K (Missense)		SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E160K	0.4694	49.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E160K (Missense)		SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.R86W	0.5	56.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.R86W (Missense)		SARC_MUTECT2	TCGA-IE-A4EI-01A-11D-A24N-09	TCGA-IE-A4EI-10A-01D-A24N-09
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.L223I	0.1081	37.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.L223I (Missense)		SARC_MUTECT2	TCGA-DX-A6YS-01A-12D-A351-09	TCGA-DX-A6YS-10A-01D-A351-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.D92V	0.4773	44.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.D92V (Missense)	1	SARC_MUTECT2	TCGA-3B-A9HZ-01A-11D-A38Z-09	TCGA-3B-A9HZ-10A-01D-A38Z-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.I67K	0.7786	131.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.I67K (Missense)	1	SARC_MUTECT2	TCGA-LI-A67I-01A-31D-A307-09	TCGA-LI-A67I-10A-01D-A307-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R130Q	0.6566	99.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130Q (Missense)	1	SARC_MUTECT2	TCGA-WK-A8Y0-01A-11D-A417-09	TCGA-WK-A8Y0-10D-01D-A41A-09
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Splice Site	p.X786_splice	0.3205	156.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.X786_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-A6BF-01A-11D-A307-09	TCGA-DX-A6BF-10A-01D-A307-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.D99Y	0.7059	17.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D99Y (Missense)		SARC_MUTECT2	TCGA-DX-A8BU-01A-11D-A37C-09	TCGA-DX-A8BU-10A-01D-A37F-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.N1079I	0.7222	36.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.N1079I (Missense)		SARC_MUTECT2	TCGA-K1-A42X-02A-11D-A24N-09	TCGA-K1-A42X-11A-11D-A24N-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.E2047K	0.3922	51.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E2047K (Missense)		SARC_MUTECT2	TCGA-SI-A71Q-01A-12D-A33E-09	TCGA-SI-A71Q-10A-01D-A33H-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.M1221R	0.4	35.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.M1221R (Missense)		SARC_MUTECT2	TCGA-DX-A8BP-01A-11D-A37C-09	TCGA-DX-A8BP-10A-01D-A37F-09
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.D142V	0.2037	54.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.D142V (Missense)	0	SARC_MUTECT2	TCGA-DX-A6YZ-01A-12D-A351-09	TCGA-DX-A6YZ-10B-01D-A351-09
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Deletion	p.D88del	0.2529	87.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.D88del (Deletion)	0	SARC_MUTECT2	TCGA-MJ-A68H-01A-11D-A307-09	TCGA-MJ-A68H-10A-01D-A307-09
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P14L	0.5059	85.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P14L (Missense)		SARC_MUTECT2	TCGA-KF-A41W-01A-11D-A24N-09	TCGA-KF-A41W-10A-01D-A24N-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.G262del	0.7647	17.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G262del (Deletion)		SARC_MUTECT2	TCGA-DX-A3UE-01A-11D-A307-09	TCGA-DX-A3UE-10A-01D-A307-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.F270del	0.6154	13.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F270del (Deletion)		SARC_MUTECT2	TCGA-DX-A8BL-01A-11D-A417-09	TCGA-DX-A8BL-10A-01D-A41A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.F113del	0.9412	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F113del (Deletion)		SARC_MUTECT2	TCGA-X2-A95T-01A-11D-A37C-09	TCGA-X2-A95T-10A-01D-A37F-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.Q192del	0.7632	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192del (Deletion)		SARC_MUTECT2	TCGA-3B-A9I0-01A-11D-A38Z-09	TCGA-3B-A9I0-10A-01D-A38Z-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.L252del	0.3103	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L252del (Deletion)		SARC_MUTECT2	TCGA-DX-AB32-01A-11D-A417-09	TCGA-DX-AB32-10A-01D-A41A-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.E271_R290delinsG	0.8	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271_R290delinsG (Deletion)		SARC_MUTECT2	TCGA-DX-A6YR-01A-33D-A351-09	TCGA-DX-A6YR-10B-01D-A351-09
Investigate Actionability		Guideline		Somatic Variant	ABL1	Frameshift	p.Y185Sfs*59	0.4762	21.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.Y185Sfs*59 (Frameshift)		SARC_MUTECT2	TCGA-DX-AB3C-01A-11D-A417-09	TCGA-DX-AB3C-10A-01D-A41A-09
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Frameshift	p.P34Hfs*81	0.0565	124.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.P34Hfs*81 (Frameshift)		SARC_MUTECT2	TCGA-X6-A8C4-01A-11D-A36J-09	TCGA-X6-A8C4-10A-01D-A36M-09
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.D733Y	0.4521	73.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.D733Y (Missense)		SARC_MUTECT2	TCGA-DX-A3LY-01B-11D-A27P-09	TCGA-DX-A3LY-10B-01D-A27P-09
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.A611T	0.2743	113.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.A611T (Missense)		SARC_MUTECT2	TCGA-QQ-A5VC-01A-31D-A32I-09	TCGA-QQ-A5VC-10A-01D-A32I-09
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R323L	0.3636	11.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R323L (Missense)		SARC_MUTECT2	TCGA-DX-A6YV-01A-12D-A351-09	TCGA-DX-A6YV-10B-01D-A351-09
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T52I	0.0926	54.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T52I (Missense)		SARC_MUTECT2	TCGA-QQ-A8VG-01A-11D-A37C-09	TCGA-QQ-A8VG-10A-01D-A37F-09
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.Q510L	0.25	60.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.Q510L (Missense)		SARC_MUTECT2	TCGA-QQ-A8VG-01A-11D-A37C-09	TCGA-QQ-A8VG-10A-01D-A37F-09
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Nonsense	p.R2008*	0.1935	31.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R2008* (Nonsense)		SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.M984L	0.0658	243.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.M984L (Missense)		SARC_MUTECT2	TCGA-DX-A6BK-01A-11D-A307-09	TCGA-DX-A6BK-10A-01D-A307-09
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T357M	0.2857	35.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T357M (Missense)		SARC_MUTECT2	TCGA-DX-A3U8-01A-11D-A29N-09	TCGA-DX-A3U8-10A-01D-A29N-09
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.G1127S	0.2679	56.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.G1127S (Missense)		SARC_MUTECT2	TCGA-DX-AB2O-01A-12D-A38Z-09	TCGA-DX-AB2O-10A-01D-A38Z-09
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S364L	0.2982	57.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S364L (Missense)		SARC_MUTECT2	TCGA-DX-AB2O-01A-12D-A38Z-09	TCGA-DX-AB2O-10A-01D-A38Z-09
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.F350L	0.2031	64.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.F350L (Missense)		SARC_MUTECT2	TCGA-DX-AB2O-01A-12D-A38Z-09	TCGA-DX-AB2O-10A-01D-A38Z-09
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.P209S	0.1944	36.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.P209S (Missense)		SARC_MUTECT2	TCGA-DX-A8BZ-01A-11D-A37C-09	TCGA-DX-A8BZ-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G169R	0.1923	78.0	0.0	0.0																									NTRK1 p.G169R (Missense)		SARC_MUTECT2	TCGA-DX-A48N-01A-11D-A307-09	TCGA-DX-A48N-10A-01D-A307-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.M379*	0.5	56.0	0.0	0.0																									RB1 p.M379* (Frameshift)		SARC_MUTECT2	TCGA-DX-A8BM-01A-11D-A417-09	TCGA-DX-A8BM-10B-01D-A41A-09
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S421F	0.3264	144.0	0.0	0.0																									IL12RB1 p.S421F (Missense)		SARC_MUTECT2	TCGA-DX-A8BM-01A-11D-A417-09	TCGA-DX-A8BM-10B-01D-A41A-09
Biologically Relevant				Somatic Variant	EML4	Missense	p.R445G	0.0789	38.0	0.0	0.0																									EML4 p.R445G (Missense)		SARC_MUTECT2	TCGA-SI-A71O-01A-12D-A33E-09	TCGA-SI-A71O-10A-01D-A33H-09
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.K439I	0.1034	58.0	0.0	0.0																									EWSR1 p.K439I (Missense)		SARC_MUTECT2	TCGA-DX-A6BA-01A-11D-A307-09	TCGA-DX-A6BA-10A-01D-A307-09
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.D850Y	0.1552	58.0	0.0	0.0																									PDGFRB p.D850Y (Missense)		SARC_MUTECT2	TCGA-IS-A3K7-01A-11D-A21Q-09	TCGA-IS-A3K7-10A-01D-A21Q-09
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.L506Afs*5	0.2042	191.0	0.0	0.0																									NF1 p.L506Afs*5 (Frameshift)		SARC_MUTECT2	TCGA-SI-A71P-01A-12D-A33E-09	TCGA-SI-A71P-10A-01D-A33H-09
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.A308Cfs*7	0.9559	68.0	0.0	0.0																									NF1 p.A308Cfs*7 (Frameshift)		SARC_MUTECT2	TCGA-DX-AB30-01A-11D-A38Z-09	TCGA-DX-AB30-10A-01D-A38Z-09
Biologically Relevant				Somatic Variant	AURKB	Missense	p.R148W	0.2143	56.0	0.0	0.0																									AURKB p.R148W (Missense)		SARC_MUTECT2	TCGA-DX-A6YZ-01A-12D-A351-09	TCGA-DX-A6YZ-10B-01D-A351-09
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X888_splice	0.1887	106.0	0.0	0.0																									RB1 p.X888_splice (Splice Site)		SARC_MUTECT2	TCGA-3B-A9I3-01A-11D-A38Z-09	TCGA-3B-A9I3-10A-01D-A38Z-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.E119Vfs*9	0.5606	66.0	0.0	0.0																									RB1 p.E119Vfs*9 (Frameshift)		SARC_MUTECT2	TCGA-X6-A7WA-01A-12D-A351-09	TCGA-X6-A7WA-10A-01D-A351-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.N623Kfs*30	0.8571	35.0	0.0	0.0																									RB1 p.N623Kfs*30 (Frameshift)		SARC_MUTECT2	TCGA-DX-A3UE-01A-11D-A307-09	TCGA-DX-A3UE-10A-01D-A307-09
Biologically Relevant				Somatic Variant	MDM2	Missense	p.I211T	0.4464	56.0	0.0	0.0																									MDM2 p.I211T (Missense)		SARC_MUTECT2	TCGA-DX-A48U-01A-11D-A307-09	TCGA-DX-A48U-10A-01D-A307-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.G801Efs*9	0.75	60.0	0.0	0.0																									RB1 p.G801Efs*9 (Frameshift)		SARC_MUTECT2	TCGA-LI-A67I-01A-31D-A307-09	TCGA-LI-A67I-10A-01D-A307-09
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.L2337Ffs*9	0.88	25.0	0.0	0.0																									NF1 p.L2337Ffs*9 (Frameshift)		SARC_MUTECT2	TCGA-QQ-A5VC-01A-31D-A32I-09	TCGA-QQ-A5VC-10A-01D-A32I-09
Biologically Relevant				Somatic Variant	NF1	Deletion	p.E2339_L2345del	0.8148	27.0	0.0	0.0																									NF1 p.E2339_L2345del (Deletion)		SARC_MUTECT2	TCGA-QQ-A5VC-01A-31D-A32I-09	TCGA-QQ-A5VC-10A-01D-A32I-09
Biologically Relevant				Somatic Variant	NF1	Missense	p.H1170Q	0.0976	123.0	0.0	0.0																									NF1 p.H1170Q (Missense)		SARC_MUTECT2	TCGA-DX-A6BG-01A-11D-A307-09	TCGA-DX-A6BG-10A-01D-A307-09
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X203_splice	0.9677	31.0	0.0	0.0																									RB1 p.X203_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-A6YV-01A-12D-A351-09	TCGA-DX-A6YV-10B-01D-A351-09
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2215_splice	0.6852	54.0	0.0	0.0																									NF1 p.X2215_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-AB2X-01A-11D-A387-09	TCGA-DX-AB2X-10A-01D-A38A-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q384*	0.5526	38.0	0.0	0.0																									RB1 p.Q384* (Nonsense)		SARC_MUTECT2	TCGA-3B-A9HP-01A-11D-A387-09	TCGA-3B-A9HP-10A-01D-A38A-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.V725Nfs*25	0.2692	26.0	0.0	0.0																									RB1 p.V725Nfs*25 (Frameshift)		SARC_MUTECT2	TCGA-DX-A7EM-01A-11D-A36J-09	TCGA-DX-A7EM-10A-01D-A36M-09
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X737_splice	0.5517	29.0	0.0	0.0																									RB1 p.X737_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-A7EM-01A-11D-A36J-09	TCGA-DX-A7EM-10A-01D-A36M-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E675*	0.9487	39.0	0.0	0.0																									RB1 p.E675* (Nonsense)		SARC_MUTECT2	TCGA-DX-A7EN-01A-11D-A38Z-09	TCGA-DX-A7EN-11A-11D-A38Z-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Y155*	0.6316	19.0	0.0	0.0																									RB1 p.Y155* (Nonsense)		SARC_MUTECT2	TCGA-3B-A9I0-01A-11D-A38Z-09	TCGA-3B-A9I0-10A-01D-A38Z-09
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A73G	0.5172	58.0	0.0	0.0																									ROS1 p.A73G (Missense)		SARC_MUTECT2	TCGA-3B-A9I1-01A-11D-A38Z-09	TCGA-3B-A9I1-10A-01D-A38Z-09
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R1362*	0.2692	52.0	0.0	0.0																									NF1 p.R1362* (Nonsense)		SARC_MUTECT2	TCGA-QQ-A8VG-01A-11D-A37C-09	TCGA-QQ-A8VG-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.R187Q	0.2035	113.0	0.0	0.0																									PDGFB p.R187Q (Missense)		SARC_MUTECT2	TCGA-QQ-A8VG-01A-11D-A37C-09	TCGA-QQ-A8VG-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	MDM2	Missense	p.D231N	0.1176	34.0	0.0	0.0																									MDM2 p.D231N (Missense)		SARC_MUTECT2	TCGA-IE-A3OV-01A-11D-A228-09	TCGA-IE-A3OV-11A-22D-A22A-09
Biologically Relevant				Somatic Variant	MLH1	Missense	p.T504S	0.6705	88.0	0.0	0.0																									MLH1 p.T504S (Missense)		SARC_MUTECT2	TCGA-DX-A6YQ-01A-12D-A33E-09	TCGA-DX-A6YQ-10A-01D-A33H-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.K574Nfs*36	0.6076	79.0	0.0	0.0																									RB1 p.K574Nfs*36 (Frameshift)		SARC_MUTECT2	TCGA-WK-A8Y0-01A-11D-A417-09	TCGA-WK-A8Y0-10D-01D-A41A-09
Biologically Relevant				Somatic Variant	PMS2	Missense	p.C331S	0.1351	185.0	0.0	0.0																									PMS2 p.C331S (Missense)		SARC_MUTECT2	TCGA-DX-AATS-01A-12D-A417-09	TCGA-DX-AATS-10A-01D-A41A-09
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X405_splice	0.3846	39.0	0.0	0.0																									RB1 p.X405_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-AB32-01A-11D-A417-09	TCGA-DX-AB32-10A-01D-A41A-09
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R1014H	0.1875	32.0	0.0	0.0																									COL1A1 p.R1014H (Missense)		SARC_MUTECT2	TCGA-DX-AB32-01A-11D-A417-09	TCGA-DX-AB32-10A-01D-A41A-09
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.K144Rfs*18	0.4783	92.0	0.0	0.0																									ESRP1 p.K144Rfs*18 (Frameshift)		SARC_MUTECT2	TCGA-DX-A3UB-01A-11D-A307-09	TCGA-DX-A3UB-10A-01D-A307-09
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.L1076F	0.292	113.0	0.0	0.0																									PDGFRB p.L1076F (Missense)		SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Biologically Relevant				Somatic Variant	POT1	Missense	p.P357S	0.3077	130.0	0.0	0.0																									POT1 p.P357S (Missense)		SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.E804K	0.5102	49.0	0.0	0.0																									FGFR1 p.E804K (Missense)		SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.T288A	0.4545	55.0	0.0	0.0																									NTRK2 p.T288A (Missense)		SARC_MUTECT2	TCGA-QC-A7B5-01A-11D-A33E-09	TCGA-QC-A7B5-11A-11D-A33H-09
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X463_splice	0.3212	274.0	0.0	0.0																									RB1 p.X463_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-A8BG-01A-12D-A417-09	TCGA-DX-A8BG-10B-01D-A41A-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.L389*	0.5714	14.0	0.0	0.0																									RB1 p.L389* (Nonsense)		SARC_MUTECT2	TCGA-K1-A6RU-01A-11D-A32I-09	TCGA-K1-A6RU-10A-01D-A32I-09
Biologically Relevant				Somatic Variant	TPX2	Missense	p.R440I	0.125	120.0	0.0	0.0																									TPX2 p.R440I (Missense)		SARC_MUTECT2	TCGA-SG-A849-01A-11D-A351-09	TCGA-SG-A849-10A-01D-A351-09
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.D337N	0.3333	21.0	0.0	0.0																									IL12RB1 p.D337N (Missense)		SARC_MUTECT2	TCGA-PC-A5DM-01A-11D-A27P-09	TCGA-PC-A5DM-10A-01D-A27P-09
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.Q209L	0.25	12.0	0.0	0.0																									RUNX1T1 p.Q209L (Missense)		SARC_MUTECT2	TCGA-QQ-A5VD-01A-21D-A32I-09	TCGA-QQ-A5VD-10A-01D-A32I-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q471*	0.1852	27.0	0.0	0.0																									RB1 p.Q471* (Nonsense)		SARC_MUTECT2	TCGA-QQ-A5VD-01A-21D-A32I-09	TCGA-QQ-A5VD-10A-01D-A32I-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R787*	0.1538	39.0	0.0	0.0																									RB1 p.R787* (Nonsense)		SARC_MUTECT2	TCGA-QQ-A5VD-01A-21D-A32I-09	TCGA-QQ-A5VD-10A-01D-A32I-09
Biologically Relevant				Somatic Variant	TACC3	Missense	p.A490S	0.129	31.0	0.0	0.0																									TACC3 p.A490S (Missense)		SARC_MUTECT2	TCGA-DX-A6YT-01A-21D-A351-09	TCGA-DX-A6YT-10B-01D-A351-09
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P483T	0.1029	68.0	0.0	0.0																									BRD4 p.P483T (Missense)		SARC_MUTECT2	TCGA-DX-A6YT-01A-21D-A351-09	TCGA-DX-A6YT-10B-01D-A351-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.I441Lfs*16	0.5926	27.0	0.0	0.0																									RB1 p.I441Lfs*16 (Frameshift)		SARC_MUTECT2	TCGA-IS-A3KA-01A-11D-A21Q-09	TCGA-IS-A3KA-10A-01D-A21Q-09
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W15*	0.5385	13.0	0.0	0.0																									CDKN2A p.W15* (Nonsense)		SARC_MUTECT2	TCGA-DX-AB2W-01A-11D-A38Z-09	TCGA-DX-AB2W-10A-01D-A38Z-09
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X313_splice	0.2955	88.0	0.0	0.0																									RB1 p.X313_splice (Splice Site)		SARC_MUTECT2	TCGA-DX-A8BO-01A-11D-A417-09	TCGA-DX-A8BO-10B-01D-A41A-09
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G578V	0.4524	42.0	0.0	0.0																									COL1A1 p.G578V (Missense)		SARC_MUTECT2	TCGA-X6-A7WC-01A-12D-A351-09	TCGA-X6-A7WC-10A-01D-A351-09
Biologically Relevant				Somatic Variant	MYC	Insertion	p.Q37dup	0.377	61.0	0.0	0.0																									MYC p.Q37dup (Insertion)		SARC_MUTECT2	TCGA-SI-AA8C-01A-11D-A387-09	TCGA-SI-AA8C-10A-01D-A38A-09
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.H166Y	0.3937	127.0	0.0	0.0																									FGFR1 p.H166Y (Missense)		SARC_MUTECT2	TCGA-DX-A3UF-01A-11D-A307-09	TCGA-DX-A3UF-10A-01D-A307-09
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.L695Rfs*8	0.4062	32.0	0.0	0.0																									NF1 p.L695Rfs*8 (Frameshift)		SARC_MUTECT2	TCGA-X9-A973-01A-11D-A387-09	TCGA-X9-A973-10A-01D-A38A-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R445*	0.78	50.0	0.0	0.0																									RB1 p.R445* (Nonsense)		SARC_MUTECT2	TCGA-IF-A4AJ-01A-11D-A24N-09	TCGA-IF-A4AJ-11A-12D-A24N-09
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.Q382E	0.2525	99.0	0.0	0.0																									RUNX1T1 p.Q382E (Missense)		SARC_MUTECT2	TCGA-DX-A6Z2-01A-12D-A36J-09	TCGA-DX-A6Z2-11A-11D-A36M-09
Biologically Relevant				Somatic Variant	RB1	Missense	p.R334I	0.5517	29.0	0.0	0.0																									RB1 p.R334I (Missense)		SARC_MUTECT2	TCGA-DX-A6Z2-01A-12D-A36J-09	TCGA-DX-A6Z2-11A-11D-A36M-09
Biologically Relevant				Somatic Variant	TACC3	Missense	p.A771T	0.7407	54.0	0.0	0.0																									TACC3 p.A771T (Missense)		SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.T342Lfs*7	0.7419	31.0	0.0	0.0																									RB1 p.T342Lfs*7 (Frameshift)		SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.P678Rfs*10	0.7692	26.0	0.0	0.0																									NF1 p.P678Rfs*10 (Frameshift)		SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.R240H	0.4444	36.0	0.0	0.0																									KEAP1 p.R240H (Missense)		SARC_MUTECT2	TCGA-QQ-A8VF-01A-11D-A37C-09	TCGA-QQ-A8VF-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X474_splice	0.5	4.0	0.0	0.0																									RB1 p.X474_splice (Splice Site)		SARC_MUTECT2	TCGA-IE-A4EI-01A-11D-A24N-09	TCGA-IE-A4EI-10A-01D-A24N-09
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.R293W	0.2048	83.0	0.0	0.0																									ESRP1 p.R293W (Missense)		SARC_MUTECT2	TCGA-VT-A80J-01A-11D-A36J-09	TCGA-VT-A80J-11A-22D-A36M-09
Biologically Relevant				Somatic Variant	RAF1	Missense	p.A620D	0.1613	31.0	0.0	0.0																									RAF1 p.A620D (Missense)		SARC_MUTECT2	TCGA-DX-A6YS-01A-12D-A351-09	TCGA-DX-A6YS-10A-01D-A351-09
Biologically Relevant				Somatic Variant	PMS2	Missense	p.P524S	0.3134	67.0	0.0	0.0																									PMS2 p.P524S (Missense)		SARC_MUTECT2	TCGA-DX-A6YS-01A-12D-A351-09	TCGA-DX-A6YS-10A-01D-A351-09
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.G631V	0.1042	48.0	0.0	0.0																									LIMK2 p.G631V (Missense)		SARC_MUTECT2	TCGA-DX-A6YS-01A-12D-A351-09	TCGA-DX-A6YS-10A-01D-A351-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.M484Vfs*8	1.0	26.0	0.0	0.0																									RB1 p.M484Vfs*8 (Frameshift)		SARC_MUTECT2	TCGA-DX-A48L-01A-11D-A307-09	TCGA-DX-A48L-10A-01D-A307-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R552*	0.7027	37.0	0.0	0.0																									RB1 p.R552* (Nonsense)		SARC_MUTECT2	TCGA-X6-A7WD-01A-21D-A351-09	TCGA-X6-A7WD-10A-01D-A351-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.K548Efs*55	0.5909	22.0	0.0	0.0																									RB1 p.K548Efs*55 (Frameshift)		SARC_MUTECT2	TCGA-WK-A8XZ-01A-11D-A37C-09	TCGA-WK-A8XZ-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.N546K	0.22	50.0	0.0	0.0																									FGFR1 p.N546K (Missense)		SARC_MUTECT2	TCGA-SI-A71Q-01A-12D-A33E-09	TCGA-SI-A71Q-10A-01D-A33H-09
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.9143	35.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		SARC_MUTECT2	TCGA-SI-A71Q-01A-12D-A33E-09	TCGA-SI-A71Q-10A-01D-A33H-09
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.R556Wfs*53	0.7451	51.0	0.0	0.0																									RB1 p.R556Wfs*53 (Frameshift)		SARC_MUTECT2	TCGA-DX-AB2T-01A-11D-A387-09	TCGA-DX-AB2T-10A-01D-A38A-09
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S796L	0.0909	66.0	0.0	0.0																									BRD4 p.S796L (Missense)		SARC_MUTECT2	TCGA-DX-A3U9-01A-11D-A307-09	TCGA-DX-A3U9-10A-01D-A307-09
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.H227Y	0.6267	150.0	0.0	0.0																									TMPRSS2 p.H227Y (Missense)		SARC_MUTECT2	TCGA-DX-A2J4-01A-32D-A21Q-09	TCGA-DX-A2J4-10A-01D-A21Q-09
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R1436C	0.1667	30.0	0.0	0.0																									COL1A1 p.R1436C (Missense)		SARC_MUTECT2	TCGA-QQ-A8VB-01A-11D-A37C-09	TCGA-QQ-A8VB-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R583C	0.413	46.0	0.0	0.0																									NTRK1 p.R583C (Missense)		SARC_MUTECT2	TCGA-DX-AB2E-01A-11D-A38Z-09	TCGA-DX-AB2E-10A-01D-A38Z-09
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.Y628Tfs*3	0.2188	32.0	0.0	0.0																									NF1 p.Y628Tfs*3 (Frameshift)		SARC_MUTECT2	TCGA-3B-A9HT-01A-11D-A38Z-09	TCGA-3B-A9HT-10A-01D-A38Z-09
Biologically Relevant				Somatic Variant	MYC	Missense	p.P59S	0.3896	77.0	0.0	0.0																									MYC p.P59S (Missense)		SARC_MUTECT2	TCGA-DX-A8BP-01A-11D-A37C-09	TCGA-DX-A8BP-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	MYC	Missense	p.P59L	0.3816	76.0	0.0	0.0																									MYC p.P59L (Missense)		SARC_MUTECT2	TCGA-DX-A8BP-01A-11D-A37C-09	TCGA-DX-A8BP-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1564F	0.3243	37.0	0.0	0.0																									NF1 p.L1564F (Missense)		SARC_MUTECT2	TCGA-DX-A8BP-01A-11D-A37C-09	TCGA-DX-A8BP-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	POT1	Missense	p.R273Q	0.15	80.0	0.0	0.0																									POT1 p.R273Q (Missense)		SARC_MUTECT2	TCGA-DX-AB2F-01A-11D-A387-09	TCGA-DX-AB2F-10A-01D-A38A-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q504*	0.9048	21.0	0.0	0.0																									RB1 p.Q504* (Nonsense)		SARC_MUTECT2	TCGA-3B-A9HY-01A-11D-A38Z-09	TCGA-3B-A9HY-10A-01D-A38Z-09
Biologically Relevant				Somatic Variant	NTRK2	Insertion	p.N350dup	0.375	48.0	0.0	0.0																									NTRK2 p.N350dup (Insertion)		SARC_MUTECT2	TCGA-X6-A8C3-01A-11D-A36J-09	TCGA-X6-A8C3-10A-01D-A36M-09
Biologically Relevant				Somatic Variant	NF1	Missense	p.G751R	0.4839	31.0	0.0	0.0																									NF1 p.G751R (Missense)		SARC_MUTECT2	TCGA-QQ-A8VH-01A-11D-A37C-09	TCGA-QQ-A8VH-10A-01D-A37F-09
Biologically Relevant				Somatic Variant	RB1	Missense	p.I724S	0.5	6.0	0.0	0.0																									RB1 p.I724S (Missense)		SARC_MUTECT2	TCGA-DX-A8BN-01A-11D-A37C-09	TCGA-DX-A8BN-11A-22D-A37F-09
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.V354I	0.4407	59.0	0.0	0.0																									NTRK1 p.V354I (Missense)		SARC_MUTECT2	TCGA-3B-A9HV-01A-11D-A38Z-09	TCGA-3B-A9HV-10A-01D-A38Z-09
Biologically Relevant				Somatic Variant	CDK4	Missense	p.G15R	0.3571	14.0	0.0	0.0																									CDK4 p.G15R (Missense)		SARC_MUTECT2	TCGA-MB-A5Y8-01A-11D-A29N-09	TCGA-MB-A5Y8-10A-01D-A29N-09
Biologically Relevant				Somatic Variant	MDM2	Missense	p.L230F	0.0462	779.0	0.0	0.0																									MDM2 p.L230F (Missense)		SARC_MUTECT2	TCGA-DX-A3LS-01A-11D-A21Q-09	TCGA-DX-A3LS-10A-01D-A21Q-09
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.D2375Efs*3	0.2115	52.0	0.0	0.0																									NF1 p.D2375Efs*3 (Frameshift)		SARC_MUTECT2	TCGA-RN-AAAQ-01A-21D-A38Z-09	TCGA-RN-AAAQ-10A-01D-A38Z-09
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH6 p.F1088Lfs*5 (Frameshift), ESRP1 p.K144Rfs*18 (Frameshift), DOCK3 p.L662* (Nonsense)																													Supporting variants: MSH6 p.F1088Lfs*5 (Frameshift), ESRP1 p.K144Rfs*18 (Frameshift), DOCK3 p.L662* (Nonsense)		SARC_MUTECT2		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.323																													COSMIC Signature (version 2) 1 (32%)		SARC_MUTECT2		
